Professor Derek Hill, Chief Executive Officer of IXICO Ltd, said: “The current approaches to medical image analysis in clinical trials rely on highly-skilled radiologists and technicians ‘reading’ and painstakingly comparing images that are often acquired at different centres and different points in time. This process is expensive, time consuming and subject to error.
Our service is completely automated and uses sensitive and reproducible algorithms to quantify changes in the patient over time and hence assess the effectiveness or ineffectiveness of a treatment during trials. It can also compensate for the misplacement or movement of a patient in the scanner, compare images taken at different points in time and provide a full audit trial of the analysis process. As our service is scaleable, it can be used to analyse thousands of images in very early drug tests or in late phase trials. The end result for patients is the faster development of new, more effective treatments for painful or life threatening conditions.”
IXICO’s service has been shown to be effective in a wide variety of medical applications though the company’s initial focus is on developing its services to assess the impact of new drugs for rheumatoid arthritis, dementia and oncology. Clients include a number of major pharmaceutical and healthcare companies, for whom IXICO designs bespoke services, and the company is in advanced negotiations with additional prospective customers.
Professor Hill said: “A key feature of our technology is that the image analysis workflows in the programmes can be easily reconfigured to suit the specific requirements of different pharmaceutical companies. And we have designed our technology platform so that their staff can access the analysis results from computers in a variety of locations via a secure web portal.”
This is IXICO’s first institutional fundraising round and follows its recent success in securing a prestigious £140,000 DTI Grant for Research & Development through the London Development Agency.
Professor Hill commented on the fundraising process: “We are delighted with the success of this funding round. We spoke to several funds but were happy to work with The Capital Fund as they were prepared to share the risk with us and our angel investors by providing vital capital on straightforward terms. They have also helped us to introduce key disciplines that will be particularly useful as we grow the business.”
The Capital Fund’s Investment Manager, Helen Reynolds, said: “IXICO has created a truly innovative technology that has the potential for use across a wide range of medical applications. We were impressed by the quality of the research behind the company’s service and the calibre of the management team, especially Derek Hill, who combine substantial experience of the healthcare industry with significant image analysis acquisition know-how. We wish Derek Hill and his team every success with their future plans.”
Construction of practical quantum computers radically simplified
05.12.2016 | University of Sussex
UT professor develops algorithm to improve online mapping of disaster areas
29.11.2016 | University of Tennessee at Knoxville
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Earth Sciences
07.12.2016 | Earth Sciences
07.12.2016 | Materials Sciences